Title | Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, A Sharrett R, Brancati FL, Coresh J |
Journal | Diabetes |
Volume | 60 |
Issue | 1 |
Pagination | 298-305 |
Date Published | 2011 Jan |
ISSN | 1939-327X |
Keywords | Adult, Alcohol Drinking, Atherosclerosis, Blood Glucose, Cholesterol, HDL, Cholesterol, LDL, Cross-Sectional Studies, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin A, Humans, Kidney Diseases, Life Style, Male, Odds Ratio, Prevalence, Prospective Studies, Racial Groups, Retinal Diseases, Risk Factors, Smoking, Triglycerides |
Abstract | OBJECTIVE: Glycated hemoglobin was recently recommended for use as a diagnostic test for diabetes. We examined the association between 2010 American Diabetes Association diagnostic cut points for glycated hemoglobin and microvascular outcomes (chronic kidney disease, end-stage renal disease [ESRD], and retinopathy) and formally tested for the presence of risk thresholds in the relationships of glycated hemoglobin with these outcomes. RESEARCH DESIGN AND METHODS: Prospective cohort and cross-sectional analyses of 11,357 participants (773 with a history of diagnosed diabetes) from the Atherosclerosis Risk in Communities (ARIC) Study. RESULTS: During a median of 14 years of follow-up of individuals without diagnosed diabetes at baseline, clinical categories of glycated hemoglobin were associated with risk of chronic kidney disease, with adjusted hazard ratios (HRs) of 1.12 (0.94-1.34) and 1.39 (1.04-1.85) for glycated hemoglobin 5.7-6.4% and ≥6.5%, respectively, as compared with CONCLUSIONS: These data from a community-based, biracial population support the use of new 2010 American Diabetes Association glycated hemoglobin cut points for the diagnosis of diabetes. |
DOI | 10.2337/db10-1198 |
Alternate Journal | Diabetes |
PubMed ID | 20978092 |
PubMed Central ID | PMC3012185 |
Grant List | N01HC55020 / HL / NHLBI NIH HHS / United States N01HC55018 / HL / NHLBI NIH HHS / United States N01-HC-55022 / HC / NHLBI NIH HHS / United States N01-HC-55016 / HC / NHLBI NIH HHS / United States P30 DK079637 / DK / NIDDK NIH HHS / United States T32 HL007024 / HL / NHLBI NIH HHS / United States N01HC55015 / HL / NHLBI NIH HHS / United States K01 DK076595 / DK / NIDDK NIH HHS / United States N01-HC-55019 / HC / NHLBI NIH HHS / United States T32 HL-007024 / HL / NHLBI NIH HHS / United States P60 DK079637 / DK / NIDDK NIH HHS / United States R01 DK076770 / DK / NIDDK NIH HHS / United States N01HC55019 / HL / NHLBI NIH HHS / United States K24 DK062222 / DK / NIDDK NIH HHS / United States R01 DK-076770 / DK / NIDDK NIH HHS / United States R21 DK-080294 / DK / NIDDK NIH HHS / United States P60 DK-079637 / DK / NIDDK NIH HHS / United States N01HC55022 / HL / NHLBI NIH HHS / United States N01-HC-55021 / HC / NHLBI NIH HHS / United States N01-HC-55015 / HC / NHLBI NIH HHS / United States K01 DK-076595 / DK / NIDDK NIH HHS / United States N01-HC-55020 / HC / NHLBI NIH HHS / United States N01HC55016 / HL / NHLBI NIH HHS / United States K24 DK-62222 / DK / NIDDK NIH HHS / United States R21 DK080294 / DK / NIDDK NIH HHS / United States N01-HC-55018 / HC / NHLBI NIH HHS / United States N01HC55021 / HL / NHLBI NIH HHS / United States |